8,11,14-Eicosatriynoic Acid
(Synonyms: 8,11,14-ETI) 目录号 : GC15338
A cyclooxygenase and lipoxygenase inhibitor
Cas No.:34262-64-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX), and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μM, and 25 μM, respectively. Also, it inhibits the actions of slow-reacting substance of anaphylaxis with an IC50 value of 10 μM [1,2].
Lipoxygenases are found widely in fungi, plants, and animals in high levels. 12-LO is involved in a number of significant disease states and may play a role in oxidative glutamate toxicity. COX enzymes play elaborate roles in human physiology and pathology, involving neuronal, immune, renal, cardiovascular, gastrointestinal, and reproductive systems. COX enzymes are blocked by aspirin and a wide variety of other non-steroidal anti-inflammatory drugs, which makes them important clinically [3]. 5-LO is involved in cancer pathobiology. It is expressed by a variety of cancer cells including colon, lung, breast, and prostate and promotes cancer cell growth and neo-angiogenesis.
In vitro: Up to now, in vitro study of 8,11,14-Eicosatriynoic Acid is still in the development stage.
In vivo: Up to now, in vivo study of 8,11,14-Eicosatriynoic Acid is still in the development stage.
References:
[1]. Goetz, J., Sprecher, H., Cornwell, D., & Panganamala, R. Inhibition of prostaglandin biosynthesis by triynoic acids. Prostaglandins. 1976; 12(2): 187-192.
[2]. Sun, F., McGuire, J., Morton, D., Pike, J., Sprecher, H., & Kunau, W. Inhibition of platelet arachidonic acid 12-lipoxygenase by acetylenic acid compounds. Prostaglandins. 1981; 21(2): 333-343.
[3]. Fitzpatrick, F. Cyclooxygenase Enzymes: Regulation and Function. Current Pharmaceutical Design. 2004; 10(6): 577-588.
| Cas No. | 34262-64-1 | SDF | |
| 别名 | 8,11,14-ETI | ||
| 化学名 | 8,11,14-eicosatriynoic acid | ||
| Canonical SMILES | CCCCCC#CCC#CCC#CCCCCCCC(O)=O | ||
| 分子式 | C20H28O2 | 分子量 | 300.4 |
| 溶解度 | ≤100mg/ml in ethanol;100mg/ml in DMSO;100mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3289 mL | 16.6445 mL | 33.2889 mL |
| 5 mM | 0.6658 mL | 3.3289 mL | 6.6578 mL |
| 10 mM | 0.3329 mL | 1.6644 mL | 3.3289 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet